Health Hope Pharma

Health Hope Pharma (HHP) is a clinical-stage oncology biopharmaceutical company headquartered in Hong Kong, with operations in the United States and the United Kingdom. The company is dedicated to developing novel oral anti-cancer drugs, aiming to provide safer and more convenient alternatives to traditional intravenous therapies. Their core technology is the proprietary Orascovery platform, which utilizes Encequidar, a potent P-glycoprotein (P-gp) inhibitor. By inhibiting the P-gp efflux pump in the intestine, Encequidar enables the effective oral absorption of chemotherapeutic agents that are typically administered intravenously, such as paclitaxel.